Moolec Science (MLECW) Current Deferred Revenue (2024 - 2025)
Moolec Science (MLECW) posted Current Deferred Revenue of $1260.0 for Q2 2025, down 99.97% sequentially from $3.9 million in Q2 2024, and down 99.97% YoY from $3.9 million in Q2 2024.
Moolec Science (MLECW) Current Deferred Revenue (2024 - 2025) Analysis & Trends
Moolec Science has reported Current Deferred Revenue for 2 years, with the latest figure at $1260.0 in Q2 2025.
- Quarterly Current Deferred Revenue fell 99.97% year-over-year to $1260.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $1260.0 (down 99.97% YoY) and the FY2025 annual result came in at $1260.0, down 99.97% from the prior year.
- Current Deferred Revenue slipped to $1260.0 in Q2 2025 per MLECW's latest filing, from $3.9 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $3.9 million in Q2 2024 and troughed at $1260.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1,260.00 |
| Jun 30, 2024 | 3.92 Mn |